| Previous Close | 82.77 |
| Open | 82.75 |
| Bid | 71.12 x 1000 |
| Ask | 71.74 x 44000 |
| Day's Range | 81.28 - 83.30 |
| 52 Week Range | 66.72 - 92.97 |
| Volume | 2,988,091 |
| Avg. Volume | 2,460,430 |
| Market Cap | 99.45B |
| Beta | 0.74 |
| PE Ratio (TTM) | 11.28 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 3.30 (3.50%) |
| Ex-Dividend Date | 2017-05-16 |
| 1y Target Est | N/A |
- Zacks•yesterday
Merck's Biosimilar Insulin Gets Tentative FDA Approval
Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.
- Reuters•yesterday
U.S. jury sides with Amphastar over Momenta in drug patent trial
A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox. The verdict by the jury in Boston came in a lawsuit by Cambridge, Massachusetts-based biotechnology company Momenta and its partner, Novartis AG's Sandoz unit, that sought nearly $940 million in damages. The jury found that while Rancho Cucamonga, California-based Amphastar had infringed Momenta's patent, it was invalid and unenforceable.
Zacks•yesterdayPharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
